share_log

Arcutis Biotherapeutics | 10-Q: Q2 2024 Earnings Report

Arcutis Biotherapeutics | 10-Q: Q2 2024 Earnings Report

Arcutis Biotherapeutics | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/15 04:18

Moomoo AI 已提取核心訊息

Arcutis Biotherapeutics reported Q2 2024 total revenue of $30.9 million, a significant increase from $5.2 million in Q2 2023, driven by strong ZORYVE product sales. ZORYVE cream 0.3% revenue grew to $17.3 million while ZORYVE foam, launched in January 2024, contributed $13.6 million. The company's net loss narrowed to $52.3 million from $71.0 million year-over-year.Research and development expenses decreased 23% to $19.3 million due to completion of Phase 3 studies, while selling, general and administrative expenses increased 27% to $58.2 million to support commercialization efforts. The company ended the quarter with $363.1 million in cash and marketable securities, strengthened by a $161.7 million public offering completed in February 2024.The company achieved several key milestones, including FDA approval of ZORYVE cream 0.15% for atopic dermatitis in July 2024 and signing strategic agreements with Sato Pharmaceuticals for Japan rights and Kowa Pharmaceuticals for U.S. primary care promotion. Management expects continued commercial momentum while advancing pipeline development of ARQ-255 for alopecia areata and ARQ-234 for atopic dermatitis.
Arcutis Biotherapeutics reported Q2 2024 total revenue of $30.9 million, a significant increase from $5.2 million in Q2 2023, driven by strong ZORYVE product sales. ZORYVE cream 0.3% revenue grew to $17.3 million while ZORYVE foam, launched in January 2024, contributed $13.6 million. The company's net loss narrowed to $52.3 million from $71.0 million year-over-year.Research and development expenses decreased 23% to $19.3 million due to completion of Phase 3 studies, while selling, general and administrative expenses increased 27% to $58.2 million to support commercialization efforts. The company ended the quarter with $363.1 million in cash and marketable securities, strengthened by a $161.7 million public offering completed in February 2024.The company achieved several key milestones, including FDA approval of ZORYVE cream 0.15% for atopic dermatitis in July 2024 and signing strategic agreements with Sato Pharmaceuticals for Japan rights and Kowa Pharmaceuticals for U.S. primary care promotion. Management expects continued commercial momentum while advancing pipeline development of ARQ-255 for alopecia areata and ARQ-234 for atopic dermatitis.
Arcutis Biotherapeutics報告2024年第二季度的營業收入爲3090萬美元，較2023年第二季度的520萬美元大幅增長，這得益於ZORYVE產品銷售的強勁表現。ZORYVE 0.3%乳膏的營業收入增長至1730萬美元，而2024年1月推出的ZORYVE泡沫貢獻了1360萬美元。公司的淨虧損從去年同期的7100萬美元縮減至5230萬美元。由於完成了第3階段研究，研發費用減少23%，降至1930萬美元，而銷售、一般和行政費用增加27%，達到5820萬美元，以支持商業化工作。公司在本季度末擁有現金及可變現證券共計36310萬美元，此金額得益於2024年2月完成的16170萬美元的...展開全部
Arcutis Biotherapeutics報告2024年第二季度的營業收入爲3090萬美元，較2023年第二季度的520萬美元大幅增長，這得益於ZORYVE產品銷售的強勁表現。ZORYVE 0.3%乳膏的營業收入增長至1730萬美元，而2024年1月推出的ZORYVE泡沫貢獻了1360萬美元。公司的淨虧損從去年同期的7100萬美元縮減至5230萬美元。由於完成了第3階段研究，研發費用減少23%，降至1930萬美元，而銷售、一般和行政費用增加27%，達到5820萬美元，以支持商業化工作。公司在本季度末擁有現金及可變現證券共計36310萬美元，此金額得益於2024年2月完成的16170萬美元的公開募股。公司實現了幾個關鍵里程碑，包括在2024年7月獲得FDA批准的ZORYVE 0.15%乳膏用於特應性皮炎，並與佐藤製藥籤署了日本授權協議，以及與河野製藥簽署了美國初級保健推廣的戰略協議。管理層預計在推進ARQ-255針對斑禿和ARQ-234針對特應性皮炎的管線開發的同時，商業勢頭將持續增強。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    多家機構看多！中國資產將全面重估：你會如何布局？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家機構唱好中國資產。 🎙️討論： 1. Deepseek引爆中國資產上漲，後市你怎麼看？ 2. 多家中國企業1月表現提升，你更看好誰？ 展开
    中國的資產重估引發熱議：牛友們在買什麼？